REPCF - RepliCel Life Sciences Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.3419
+0.0328 (+10.61%)
At close: 10:36AM EDT
Stock chart is not supported by your current browser
Previous Close0.3091
Open0.3194
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3194 - 0.3419
52 Week Range0.2460 - 0.5190
Volume23,703
Avg. Volume13,327
Market Cap7.331M
Beta (3Y Monthly)-0.50
PE Ratio (TTM)N/A
EPS (TTM)-0.1060
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire2 days ago

    RepliCel Announces Federal Grant Funding for Collaboration with the University of Victoria, Canada

    VANCOUVER and VICTORIA, BC, Oct. 18, 2018 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company") is pleased to announce it has signed a collaborative research project agreement with the University of Victoria ("UVic") in Victoria, B.C., Canada. The project will be co-funded through a grant from the National Science and Engineering Research Council of Canada ("NSERC") under the NSERC Collaborative Research and Development ("CRD") program.

  • RepliCel Life Sciences Appoints New Chief Financial Officer
    CNW Group3 days ago

    RepliCel Life Sciences Appoints New Chief Financial Officer

    VANCOUVER , Oct. 17, 2018 /CNW/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announces that its board of directors has appointed Simon Ma as the Chief Financial Officer of the Company.  Mr. Ma is the current Director of Finance and succeeds Tom Kordyback who has resigned as the Chief Financial Officer to enjoy his full-time retirement from professional service. Mr. Ma is a Chartered Professional Accountant and has extensive experience with private and public companies. Simon Ma has been a sole public practitioner since 1997 and is practicing under the name of Simon S. Ma Corporation.

  • PR Newswire3 days ago

    RepliCel Life Sciences Appoints New Chief Financial Officer

    VANCOUVER, Oct. 17, 2018 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announces that its board of directors has appointed Simon Ma as the Chief Financial Officer of the Company.  Mr. Ma is the current Director of Finance and succeeds Tom Kordyback who has resigned as the Chief Financial Officer to enjoy his full-time retirement from professional service. Mr. Ma is a Chartered Professional Accountant and has extensive experience with private and public companies. Simon Ma has been a sole public practitioner since 1997 and is practicing under the name of Simon S. Ma Corporation.

  • RepliCel CEO Provides Updated Outlook
    CNW Group5 days ago

    RepliCel CEO Provides Updated Outlook

    VANCOUVER , Oct. 15, 2018 /CNW/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to provide an update to shareholders from its President and CEO, Mr. R. Lee Buckler . Now that we have closed our deal with YOFOTO, I am very pleased to provide this updated outlook. In January, I outlined our progress over the past 24 months and included our goals for 2018 which, I said, would be focused on "...leveraging partnerships to drive the Company towards maturation." Last week, we announced we had closed an investment with YOFOTO ( China ) Health Industry Co. Ltd ("YOFOTO"), which is now a significant shareholder and business partner.

  • PR Newswire5 days ago

    RepliCel CEO Provides Updated Outlook

    VANCOUVER, Oct. 15, 2018 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to provide an update to shareholders from its President and CEO, Mr. R. Lee Buckler. Now that we have closed our deal with YOFOTO, I am very pleased to provide this updated outlook. In January, I outlined our progress over the past 24 months and included our goals for 2018 which, I said, would be focused on "...leveraging partnerships to drive the Company towards maturation." Last week, we announced we had closed an investment with YOFOTO (China) Health Industry Co. Ltd ("YOFOTO"), which is now a significant shareholder and business partner.

  • RepliCel Life Sciences Completes Financing with YOFOTO (China) Health
    CNW Group9 days ago

    RepliCel Life Sciences Completes Financing with YOFOTO (China) Health

    VANCOUVER and NINGBO, China , Oct, 11, 2018 /CNW/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has completed the anticipated strategic investment (the "Transaction") with YOFOTO ( China ) Health Industry Co. Ltd. ("YOFOTO").

  • PR Newswire9 days ago

    RepliCel Life Sciences Completes Financing with YOFOTO (China) Health

    VANCOUVER and NINGBO, China, Oct, 11, 2018 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has completed the anticipated strategic investment (the "Transaction") with YOFOTO (China) Health Industry Co. Ltd. ("YOFOTO").

  • RepliCel Life Sciences and YOFOTO (China) Health Obtain All Approvals Needed to Complete Investment
    CNW Group26 days ago

    RepliCel Life Sciences and YOFOTO (China) Health Obtain All Approvals Needed to Complete Investment

    VANCOUVER and NINGBO, China , Sept. 24, 2018 /CNW/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has received, from the TSX Venture Exchange, the conditional approval required to complete the investment which is part of a previously announced collaboration agreement (the "Transaction") focused on commercialization of select RepliCel products in Greater China .

  • PR Newswire26 days ago

    RepliCel Life Sciences and YOFOTO (China) Health Obtain All Approvals Needed to Complete Investment

    VANCOUVER and NINGBO, China, Sept. 24, 2018 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has received, from the TSX Venture Exchange, the conditional approval required to complete the investment which is part of a previously announced collaboration agreement (the "Transaction") focused on commercialization of select RepliCel products in Greater China. The Company also announces that YOFOTO (China) Health Industry Co. Ltd. ("YOFOTO") has received all the approvals from the Chinese regulatory authorities required to finalize the transaction.

  • PR Newswire3 months ago

    RepliCel Life Sciences Announces Signed Licensing and Co-Development Deal for Greater China

    VANCOUVER and NINGBO, Zhejiang Province, China, July 11, 2018 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has now signed definitive agreements with YOFOTO (China) Health Industry Co. Ltd. ("YOFOTO") sealing its partnership to commercialize three of RepliCel's programs in Greater China.

  • RepliCel Life Sciences Announces Signed Licensing and Co-Development Deal for Greater China
    CNW Group3 months ago

    RepliCel Life Sciences Announces Signed Licensing and Co-Development Deal for Greater China

    VANCOUVER and NINGBO, Zhejiang Province , China , July 11, 2018 /CNW/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has now signed definitive agreements with YOFOTO ( China ) Health Industry Co. Ltd. ("YOFOTO") sealing its partnership to commercialize three of RepliCel's programs in Greater China .

  • RepliCel Life Sciences Now Finalizing its Strategic Investment Partnership with China-based YOFOTO
    CNW Group6 months ago

    RepliCel Life Sciences Now Finalizing its Strategic Investment Partnership with China-based YOFOTO

    VANCOUVER and NINGBO , Zhejiang Province , China , May 2, 2018 /CNW/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it now has a new Binding Term Sheet (the "Term Sheet") with YOFOTO ( China ) Health Industry Co. Ltd. ("YOFOTO") which both parties believe represents a stronger deal for both sides and positions them to finalize the transaction in the very near-term.

  • PR Newswire9 months ago

    RepliCel CEO Provides 2018 Shareholder Update

    VANCOUVER, Jan. 25, 2018 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to provide an update to shareholders from its President and CEO, Mr. R. Lee Buckler. The Company had a very successful 2017, which has only paved the way for a successful year as we enter into 2018. Looking back over the past 24 months, 2016 was about restructuring and refinancing the Company,  2017 was about delivering promised clinical and injector milestones, and now 2018 is about expansion.

  • RepliCel CEO Provides 2018 Shareholder Update
    CNW Group9 months ago

    RepliCel CEO Provides 2018 Shareholder Update

    RepliCel CEO Provides 2018 Shareholder Update

  • PR Newswire9 months ago

    RepliCel Life Sciences Lands Commitment for Key Investment Partnership

    VANCOUVER and NINGBO, Zhejiang Province, China, Jan. 16, 2018 /PRNewswire/ - RepliCel Life Sciences Inc. (REPCF) (RP.V) (P6P2.F) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has signed a Binding Term Sheet (the "Term Sheet") with YOFOTO (China) Health Industry Co. Ltd. ("YOFOTO") to form a strategic partnership (the "Transaction") in Greater China (Mainland China, Hong Kong, Macau, and Taiwan) (the "Territory").

  • RepliCel Life Sciences Lands Commitment for Key Investment Partnership
    CNW Group9 months ago

    RepliCel Life Sciences Lands Commitment for Key Investment Partnership

    RepliCel Life Sciences Lands Commitment for Key Investment Partnership